Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAloha Care Step Therapy Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentAloha CarePolicy H5969_003_ST2601_C

    2026 AlohaCare Advantage (HMO D-SNP) Drugs with Step Therapy Requirements

    Customize your policy alerts

    Sign up for Aloha Care Policy H5969_003_ST2601_C alerts

    Get alerted when Policy H5969_003_ST2601_C changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This formulary policy identifies AlohaCare Advantage HMO D-SNP drugs that require members to try specified alternative medications before coverage of affected drugs. It applies to listed pharmacy products and includes continuation-of-prior-therapy provisions where stated.

    Policy Summary
    PayerAloha Care
    Policy2026 AlohaCare Advantage (HMO D-SNP) Drugs with Step Therapy Requirements
    Policy CodePolicy H5969_003_ST2601_C
    Change TypeNo material change
    Effective DateSep 1, 2026
    Next Review DateNot specified
    Key ActionBefore coverage of an affected product, document the required trial of the applicable alternative drug or drugs.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6Therapeutic step-therapy categories
    14Affected product listings
    2Generic antidepressant trials required
    2Generic atypical antipsychotic trials required

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    New starts only
    Zonisade step requirement

    Coverage Criteria

    Actinic keratosis

    Covered after the required trial.

    Required alternative trial: Trial of either topical fluorouracil or topical imiquimod1 of 2 alternatives

    Required before diclofenac sodium gel 3% coverage

    Antidepressants

    Covered after the required trials.

    Generic antidepressant trials: Trial of two generics of the following formulary products: bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine hydrochloride2 generic products

    Continuation of prior therapy is approved

    Atypical antipsychotics

    Covered after the required trials.

    Generic atypical antipsychotic trials: Trial of two of the following oral generic formulary atypical antipsychotic agents: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone2 generic agents

    Continuation of prior therapy is approved

    Invega Hafyera

    Covered after one required trial.

    Prior Invega therapy: Trial of Invega Sustenna or Invega Trinza1 of 2 alternatives

    Step applies to new starts only; continuation of prior therapy is approved

    Relistor

    Covered after one required trial.

    Required constipation therapy trial: Trial of lubiprostone, Constulose, Enulose, Generlac, lactulose, or Movantik1 of 6 alternatives

    Required before Relistor coverage

    Rytary

    Covered after one required trial.

    Generic carbidopa/levodopa trial: Trial of one generic carbidopa/levodopa-containing formulation1 generic formulation

    Required before Rytary coverage

    Rytary initial therapy

    Rytary requires step therapy.

    Required prior therapy: Trial of one generic carbidopa/levodopa-containing formulation

    Zonisade initial therapy

    Zonisade requires step therapy for new starts.

    Required prior therapy: Trial of generic zonisamide capsule

    Applies to new starts only; continuation of prior therapy is approved.

    Provider Documentation Requirements

    Documentation Required

    Document Required Prerequisite Therapy

    Before coverage of a drug subject to step therapy, document the required alternative trial for the applicable condition. Continuation of prior therapy may be approved when the policy specifies continuation provisions.

    • Document the required prerequisite trial in the member’s medical record.
    • Include the alternative medication(s) tried and relevant response, intolerance, or treatment history.
    • For criteria that permit continuation, document that the member is continuing established prior therapy.
    Step Therapy

    Rytary Generic Trial Required

    For Rytary, document a trial of a generic carbidopa/levodopa-containing formulation before requesting coverage.

    • Affected product: Rytary.
    • Required trial: one generic carbidopa/levodopa-containing formulation.

    Policy Background

    This formulary step-therapy policy applies to selected AlohaCare Advantage HMO D-SNP pharmacy products. Before coverage of an affected drug, the member generally must first try the specified formulary alternative or alternatives for the applicable condition. The policy addresses therapies in dermatology for actinic keratosis, psychiatry and psychosis treatment, opioid-induced constipation, and Parkinson disease therapy.

    The required trial may be one alternative or, for selected antidepressant and atypical antipsychotic products, two generic formulary agents. New-start-only requirements and continuation-of-prior-therapy exceptions apply where stated, including for Invega Hafyera and Zonisade.

    Initial Therapy Requirements

    Diclofenac sodium gel 3%

    The following is required before initial coverage.

    Topical alternative trial: Trial of either topical fluorouracil or topical imiquimod1 of 2 alternatives

    Affected antidepressants

    The following is required before initial coverage of the affected antidepressant products.

    Generic antidepressant trials: Trial of two generics of bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine hydrochloride2 generic products

    Affected atypical antipsychotics

    Continuation of Prior Therapy

    Antidepressant continuation

    Continuation of prior therapy is approved for applicable antidepressant products.

    Continuation therapy: Approve for continuation of prior therapy

    Applies to the antidepressant products listed in this category

    Atypical antipsychotic continuation

    Continuation of prior therapy is approved for applicable atypical antipsychotic products.

    Continuation therapy: Approve for continuation of prior therapy

    Applies to the atypical antipsychotic products listed in this category

    Invega Hafyera continuation

    Continuation of prior therapy is approved for Invega Hafyera.

    Required Alternative Trials

    StepRequired trialAffected product
    1Trial of either topical fluorouracil or topical imiquimodDiclofenac sodium gel 3%
    StepRequired trialAffected products
    1Trial of two generic formulary antidepressants: bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, or venlafaxine hydrochlorideEmsam; Exxua; Exxua Titration Pack; Fetzima; Fetzima Titration Pack
    StepRequired trialAffected products
    1Trial of two oral generic formulary atypical antipsychotic agents: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidoneFanapt; Fanapt Titration Pack A; Fanapt Titration Pack B; Fanapt Titration Pack C; Lybalvi; Secuado
    StepRequired trialCoverage notes
    1Trial of Invega Sustenna or Invega TrinzaInvega Hafyera; new starts only. Continuation of prior therapy is approved.
    StepRequired trialAffected product
    1Trial of lubiprostone, Constulose, Enulose, Generlac, lactulose, or MovantikRelistor
    StepRequired trialAffected product
    1Trial of one generic carbidopa/levodopa-containing formulationRytary
    StepRequired prior therapy
    1Trial of one generic carbidopa/levodopa-containing formulation
    StepRequired trialCoverage notes
    1Trial of generic zonisamide capsuleZonisade; new starts only. Continuation of prior therapy is approved.
    Policy Summary
    PayerAloha Care
    Policy2026 AlohaCare Advantage (HMO D-SNP) Drugs with Step Therapy Requirements
    Policy CodePolicy H5969_003_ST2601_C
    Change TypeNo material change
    Effective DateSep 1, 2026
    Next Review DateNot specified
    Key ActionBefore coverage of an affected product, document the required trial of the applicable alternative drug or drugs.
    SourceLink
    On This Page
    Coverage CriteriaProvider Documentation RequirementsPolicy BackgroundInitial Therapy RequirementsContinuation of Prior TherapyRequired Alternative Trials
    Step Therapy

    Zonisade New-Start Requirement

    For new starts of Zonisade, document a trial of generic zonisamide capsule before requesting coverage. Continuation of prior therapy may be approved.

    • Affected product: Zonisade.
    • Required trial: generic zonisamide capsule.
    • The step requirement applies to new starts only; document continuation of prior therapy when applicable.
    Step Therapy

    Actinic Keratosis Prerequisite

    Before requesting coverage of diclofenac sodium gel 3% for actinic keratosis, document a trial of either topical fluorouracil or topical imiquimod.

    • Required alternative trial: topical fluorouracil or topical imiquimod.
    Step Therapy

    Antidepressant Prerequisite

    For the affected antidepressant products, document trials of two generic formulary products from the specified list. Continuation of prior therapy may be approved.

    • Affected products: Emsam, Exxua, Exxua Titration Pack, Fetzima, and Fetzima Titration Pack.
    • Document trials of two generics: bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, or venlafaxine hydrochloride.
    Step Therapy

    Atypical Antipsychotic Prerequisite

    Before requesting coverage of the affected atypical antipsychotic products, document trials of two oral generic formulary atypical antipsychotic agents. Continuation of prior therapy may be approved.

    • Affected products: Fanapt, Fanapt Titration Pack A, Fanapt Titration Pack B, Fanapt Titration Pack C, Lybalvi, and Secuado.
    • Document trials of two: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone.
    Step Therapy

    Invega Hafyera Prerequisite

    For Invega Hafyera, document a trial of Invega Sustenna or Invega Trinza before requesting coverage. The step applies to new starts only, and continuation of prior therapy may be approved.

    • Required trial: Invega Sustenna or Invega Trinza.
    • Affected product: Invega Hafyera.
    • For continuation requests, document prior therapy.
    Step Therapy

    Relistor Prerequisite

    Before requesting coverage of Relistor, document a trial of at least one listed alternative medication.

    • Affected product: Relistor.
    • Acceptable alternatives: lubiprostone, Constulose, Enulose, Generlac, lactulose, or Movantik.
    Step Therapy

    Rytary Step Requirement

    For Rytary, document a trial of one generic formulation containing carbidopa/levodopa before submitting the coverage request.

    • Affected product: Rytary.
    • The prerequisite is one generic carbidopa/levodopa-containing formulation.
    Documentation Required

    Highlight the Required Rytary Trial

    The required Rytary step is a trial of one generic carbidopa/levodopa-containing formulation.

    • Complete and document the generic carbidopa/levodopa-containing formulation trial before requesting Rytary.
    Step Therapy

    Zonisade New-Start Step and Continuation

    For a new Zonisade start, document a trial of generic zonisamide capsule. The step applies only to new starts; continuation of prior therapy may be approved.

    • Required new-start step: generic zonisamide capsule.
    • Document continuation of prior therapy when applicable.
    Denial Risk

    Required Step Therapy Not Completed

    If the required step therapy has not been completed or adequately documented, coverage may be denied.

    • Submit documentation of the applicable prerequisite trial with the request.
    • If the required alternative trial is absent, the request may not meet coverage criteria.

    The following is required before initial coverage of the affected atypical antipsychotic products.

    Generic atypical antipsychotic trials: Trial of two of asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone2 generic agents

    Invega Hafyera

    Required for new starts of Invega Hafyera.

    Prior paliperidone injection trial: Trial of Invega Sustenna or Invega Trinza1 of 2 alternatives

    Step applies to new starts only

    Relistor

    The following is required before initial coverage.

    Constipation therapy trial: Trial of lubiprostone, Constulose, Enulose, Generlac, lactulose, or Movantik1 of 6 alternatives

    Rytary

    The following is required before initial coverage.

    Generic carbidopa/levodopa trial: Trial of one generic carbidopa/levodopa-containing formulation1 generic formulation

    Rytary

    Rytary requires step therapy.

    Prior generic trial: Trial of one generic carbidopa/levodopa-containing formulation

    Zonisade

    Zonisade requires step therapy for new starts.

    Prior generic trial: Trial of generic zonisamide capsule

    Step applies to new starts only.

    Continuation therapy: Approve for continuation of prior therapy

    The step requirement applies to new starts only

    Zonisade continuation therapy

    Continuation of prior therapy is approved.

    Continuation exception: Patient is continuing prior Zonisade therapy

    The step requirement applies to new starts only.